Trevena, Inc. (TRVN)

NASDAQ: TRVN · IEX Real-Time Price · USD
0.460
+0.001 (0.31%)
At close: Mar 28, 2024, 4:00 PM
0.456
-0.004 (-0.89%)
After-hours: Mar 28, 2024, 7:53 PM EDT

Company Description

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders.

Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Trevena, Inc.
Trevena logo
Country United States
Founded 2007
IPO Date Jan 31, 2014
Industry Biotechnology
Sector Healthcare
Employees 35
CEO Ms. Carrie L. Bourdow

Contact Details

Address:
955 Chesterbrook Boulevard, Suite 110
Chesterbrook, Pennsylvania 19087
United States
Phone (610) 354-8840
Website trevena.com

Stock Details

Ticker Symbol TRVN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001429560
CUSIP Number 89532E109
ISIN Number US89532E2081
SIC Code 2834

Key Executives

Name Position
Carrie L. Bourdow President, Chief Executive Officer and Chairman
Barry Shin Executive Vice President, Chief Operating Officer and Chief Financial Officer
Dr. Mark A. Demitrack M.D. Senior Vice President and Chief Medical Officer
Dr. Howard A. Rockman M.D. Scientific Founder, Consultant and Member of Scientific Advisory Board
Joel Solomon Vice President, General Counsel and Chief Compliance Officer
Michael Catalano Vice President of Marketing
Robert T. Yoder Senior Vice President, Chief Business Officer and Head of Commercial Operations
Patricia M. Drake Senior Vice President and Chief Commercial Officer

Latest SEC Filings

Date Type Title
Mar 21, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 21, 2024 8-K Current Report
Mar 6, 2024 8-K Current Report
Feb 20, 2024 DEF 14A Other definitive proxy statements
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 PRE 14A Other preliminary proxy statements
Feb 1, 2024 8-K Current Report
Jan 23, 2024 424B3 Prospectus
Jan 22, 2024 EFFECT Notice of Effectiveness
Jan 19, 2024 S-3/A [Amend] Registration statement under Securities Act of 1933